2 weeks ago
Natco Pharma Q1 profit slumps 57% on weak Lenalidomide sales
Natco Pharma is a company in Mumbai, India, that makes medicines.
It makes many medicines, including a cancer-treating drug called lenalidomide.
The company shared its money results for the first three months ending June 2026.
Its profit fell by 57 percent compared with the same time last year.
This happened because sales of lenalidomide were much lower.
The company's total revenue also dropped sharply, mostly from medicines sold abroad.
However, some parts of the business grew, such as medicines sold inside India.
The company also spent less money, which helped a little.
Natco Pharma's consolidated net profit declined 57% to Rs 206.5 crore in Q1 ended June 2026.
The company posted a net profit of Rs 480.3 crore in the same quarter last fiscal.
Consolidated revenue from operations fell to Rs 735.2 crore from Rs 1,328.9 crore a year earlier.
The decline was largely driven by lower lenalidomide revenue, partially offset by growth in the base business.
Domestic formulations revenue rose to Rs 136.4 crore, while international formulations fell to Rs 477.1 crore.
- Who
- Natco Pharma Ltd, an Indian pharmaceutical company based in Mumbai
- What
- Reported a 57% decline in consolidated net profit to Rs 206.5 crore for the first quarter due to lower lenalidomide sales
- Where
- Mumbai, India
- When
- First quarter ended June 2026, reported on a Friday
- Why
- Lower revenue from the generic cancer drug lenalidomide, partially offset by growth in the base business
Key facts
- Company
- Natco Pharma Ltd
- Quarter
- Q1 ended June 2026
- Net Profit
- Rs 206.5 crore (down 57% YoY)
- Year-Ago Net Profit
- Rs 480.3 crore
- Revenue from Operations
- Rs 735.2 crore (vs Rs 1,328.9 crore)
- Total Expenses
- Rs 608.8 crore (vs Rs 818.7 crore)
- Domestic Formulations Revenue
- Rs 136.4 crore (up from Rs 107 crore)
- International Formulations Revenue
- Rs 477.1 crore (down from Rs 1,120.9 crore)









